May 15, 2017

Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma. HUD designation covers devices that treat rare, orphan diseases or… Read More
learn more
May 15, 2017

Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma. HUD designation covers devices that treat rare, orphan diseases or… Read More
learn more
May 11, 2017

Martin J. Madden Joins Novocure Board of Directors

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novocure’s 2017 annual general meeting of shareholders. In addition, Mr. Madden has been appointed to Novocure’s Audit and Nominating and Corporate… Read More
learn more
May 11, 2017

Martin J. Madden Joins Novocure Board of Directors

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novocure’s 2017 annual general meeting of shareholders. In addition, Mr. Madden has been appointed to Novocure’s Audit and Nominating and Corporate… Read More
learn more
May 8, 2017

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients

Addition of Optune to temozolomide did not negatively impact quality of life for newly diagnosed glioblastoma patients except for causing itchy skin ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ:NVCR) announced today results from health-related quality of life analyses from its phase 3, pivotal EF-14 trial adding… Read More
learn more
May 8, 2017

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients

Addition of Optune to temozolomide did not negatively impact quality of life for newly diagnosed glioblastoma patients except for causing itchy skin ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ:NVCR) announced today results from health-related quality of life analyses from its phase 3, pivotal EF-14 trial adding… Read More
learn more
May 4, 2017

Novocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas

Trials sponsored by the Pediatric Brain Tumor Consortium and Hackensack University Medical Center now open and recruiting ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today two pilot trials are open and actively recruiting pediatric patients with high grade gliomas to evaluate the safety and feasibility of Tumor… Read More
learn more
May 4, 2017

Novocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas

Trials sponsored by the Pediatric Brain Tumor Consortium and Hackensack University Medical Center now open and recruiting ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today two pilot trials are open and actively recruiting pediatric patients with high grade gliomas to evaluate the safety and feasibility of Tumor… Read More
learn more
May 1, 2017

Novocure to Present at Three Upcoming Investor Conferences in May

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in three upcoming investor conferences in May. William Doyle, Novocure’s Executive Chairman, will participate in a fireside chat at the Deutsche Bank 42nd Annual Health Care Conference on May 4, 2017, in Boston. Mr. Doyle’s… Read More
learn more
May 1, 2017

Novocure to Present at Three Upcoming Investor Conferences in May

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in three upcoming investor conferences in May. William Doyle, Novocure’s Executive Chairman, will participate in a fireside chat at the Deutsche Bank 42nd Annual Health Care Conference on May 4, 2017, in Boston. Mr. Doyle’s… Read More
learn more